Cochrane · systematic review · CD007477
Deferasirox for managing transfusional iron overload in people with sickle cell disease
Meerpohl, JJ, Schell, LK, Rücker, G, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 28.6%Low 1 · 14.3%Moderate 4 · 57.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyDeferasirox versus deferoxamine for managing transfusional iron overload in people with sickle cell disease
Population: patients with sickle cell disease and transfusional iron overload
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Deferasirox vs deferoxamine | RR 1.26 [0.05, 30.41] | 1 study · 191 participants | Very low Downgraded: risk of bias |
End‐organ damage (incidence of diabetes) Deferasirox vs deferoxamine | RR 1.26 [0.05, 30.41] | 1 study · 191 participants | Very low Downgraded: risk of bias |
LIC measured by SQUID biomagnetometer (mg Fe/g dw); overall population adjusted for transfusion category Deferasirox vs deferoxamine | no estimate extracted | 1 study · 173 participants | Moderate Downgraded: risk of bias |
Serum ferritin (µg/l) Deferasirox vs deferoxamine | no estimate extracted | 2 studies · 283 participants | Moderate Downgraded: risk of bias |
AE: Change in creatinine from baseline (µmol/l) Deferasirox vs deferoxamine | no estimate extracted | 1 study · 195 participants | Moderate Downgraded: risk of bias |
Discontinuations Deferasirox vs deferoxamine | RR 0.53 [0.31, 0.92] | 2 studies · 398 participants | Low Downgraded: risk of bias, inconsistency |
Satisfaction Deferasirox vs deferoxamine | RR 3.13 [1.99, 4.93] | 1 study · 195 participants | Moderate Downgraded: risk of bias |
Deferasirox compared to Deferoxamine for managing transfusional iron overload in people with sickle cell disease
Population: patients with managing transfusional iron overload in people with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality ‐ not measured Deferasirox vs Deferoxamine | no estimate extracted | NR | No studies |
End‐organ damage ‐ not measured Deferasirox vs Deferoxamine | no estimate extracted | NR | No studies |
LIC measured by SQUID Biomagnetometer; Overall population adjusted for transfusion category Deferasirox vs Deferoxamine | no estimate extracted | 1 study · 173 participants | Moderate Downgraded: risk of bias |
Serum ferritin (µg/l) Deferasirox vs Deferoxamine | no estimate extracted | 1 study · 116 participants | Moderate Downgraded: risk of bias |
AE: Creatinine increase Deferasirox vs Deferoxamine | RR 1.64 [0.98, 2.74] | 1 study · 195 participants | Moderate Downgraded: risk of bias |
Discontinuations Deferasirox vs Deferoxamine | RR 1.67 [0.36, 7.81] | 1 study · 195 participants | Moderate Downgraded: risk of bias |
Satisfaction Deferasirox vs Deferoxamine | RR 3.56 [2, 6.35] | 1 study · 195 participants | Low Downgraded: risk of bias |